DUBLIN, Sept. 9, 2022 /PRNewswire/ — The “Calcifediol Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s offering.
Increasing expenditures on advanced pharmaceutical ingredients (API) manufacturing in emerging economies such as China and India is expected to keep the calcifediol monohydrate market growing.
Furthermore, the global prevalence of chronic kidney disease (CKD) is increasing as a result of changing dietary patterns and a fast-paced work environment, which is boosting the demand for calcifediol monohydrate-based medications. According to the National Centre for Chronic Disease Prevention and Health Promotion (USA), chronic kidney disease affects about 15% of the population in the United States (CKD).
Additionally, the higher incidence of rickets and brittle bones is predicted to boost this industry’s growth. According to the Centers for Disease Control and Prevention, rickets affects 5 out of every 1,000,000 children aged 6 months to 5 years.
Also, companies are investing heavily in research and development. Because of the advantageous legislation regulating the manufacture and sale of vitamin D analogues and vitamin D3 APIs, leading manufacturers are locating their manufacturing facilities in Europe.
On the other hand, due to the high concentration and purity of vitamin D, the manufacture of this chemical necessitates the use of technologically advanced machinery and high monetary backup, along with factors affecting…
